ZA201001193B - 2-anilinopurin-8-ones as inhibitors of TTK/MPS1 for the treatment of proliferative disorders - Google Patents

2-anilinopurin-8-ones as inhibitors of TTK/MPS1 for the treatment of proliferative disorders

Info

Publication number
ZA201001193B
ZA201001193B ZA201001193A ZA201001193A ZA201001193B ZA 201001193 B ZA201001193 B ZA 201001193B ZA 201001193 A ZA201001193 A ZA 201001193A ZA 201001193 A ZA201001193 A ZA 201001193A ZA 201001193 B ZA201001193 B ZA 201001193B
Authority
ZA
South Africa
Prior art keywords
anilinopurin
mps1
ttk
inhibitors
ones
Prior art date
Application number
ZA201001193A
Other languages
English (en)
Inventor
David Michael Andrews
Clifford David Jones
Iain Simpson
Richard Andrew Ward
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA201001193B publication Critical patent/ZA201001193B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA201001193A 2007-08-23 2010-02-18 2-anilinopurin-8-ones as inhibitors of TTK/MPS1 for the treatment of proliferative disorders ZA201001193B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95750807P 2007-08-23 2007-08-23

Publications (1)

Publication Number Publication Date
ZA201001193B true ZA201001193B (en) 2010-10-27

Family

ID=39951669

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA201001193A ZA201001193B (en) 2007-08-23 2010-02-18 2-anilinopurin-8-ones as inhibitors of TTK/MPS1 for the treatment of proliferative disorders

Country Status (19)

Country Link
US (1) US20110118238A1 (fr)
EP (1) EP2212326A1 (fr)
JP (1) JP2010536841A (fr)
KR (1) KR20100057650A (fr)
CN (1) CN103298814A (fr)
AU (1) AU2008290330A1 (fr)
BR (1) BRPI0815709A2 (fr)
CA (1) CA2696200A1 (fr)
CO (1) CO6260060A2 (fr)
CR (1) CR11295A (fr)
DO (1) DOP2010000064A (fr)
EA (1) EA201000341A1 (fr)
EC (1) ECSP10010034A (fr)
MX (1) MX2010002115A (fr)
NI (1) NI201000032A (fr)
NZ (1) NZ584138A (fr)
SV (1) SV2010003491A (fr)
WO (1) WO2009024824A1 (fr)
ZA (1) ZA201001193B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2343297A1 (fr) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343294A1 (fr) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines substituées
EP2343295A1 (fr) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Dérivés de triazolopyridine
FR2955109B1 (fr) 2010-01-08 2012-09-07 Sanofi Aventis Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
UY33452A (es) 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
TW201219383A (en) 2010-08-02 2012-05-16 Astrazeneca Ab Chemical compounds
US20130303532A1 (en) * 2010-12-17 2013-11-14 Bayer Intellectual Property Gmbh Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
US20140187548A1 (en) * 2010-12-17 2014-07-03 Bayer Intellectual Property Gmbh 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
JP2013545779A (ja) * 2010-12-17 2013-12-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン
US9284317B2 (en) * 2010-12-17 2016-03-15 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors
JP5822944B2 (ja) * 2010-12-17 2015-11-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための２置換イミダゾピラジン
ES2530802T3 (es) * 2010-12-17 2015-03-06 Bayer Ip Gmbh Imidazopirazinas 6-tiosustituidas para uso como inhibidores de MPS-1 y TKK en el tratamiento de trastornos hiperproliferativos
PT2699575E (pt) 2011-04-21 2015-07-29 Bayer Ip Gmbh Triazolopiridinas
WO2012160029A1 (fr) 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Triazolopyridines substituées
UA112096C2 (uk) 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
EP2825540B1 (fr) 2012-03-14 2016-09-14 Bayer Intellectual Property GmbH Imidazolpyridazines substituées
SG11201408419QA (en) 2012-07-10 2015-01-29 Bayer Pharma AG Method for preparing substituted triazolopyridines
WO2014020043A1 (fr) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinaisons pour le traitement du cancer
ES2626989T3 (es) * 2013-06-07 2017-07-26 Bayer Pharma Aktiengesellschaft Triazolopiridinas sustituidas
CN105377848A (zh) 2013-06-11 2016-03-02 拜耳制药股份公司 取代的三唑并吡啶的前体药物衍生物
GB201403536D0 (en) * 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
ES2966392T3 (es) 2015-04-17 2024-04-22 Crossfire Oncology Holding B V Biomarcadores pronósticos para quimioterapia inhibidora de TTK
CN110177791B (zh) 2016-12-20 2022-07-12 阿斯利康(瑞典)有限公司 氨基-三唑并吡啶化合物及其在治疗癌症中的用途
US11052091B2 (en) 2016-12-21 2021-07-06 Ono Pharmaceutical Co., Ltd. BRK inhibitory compound
TWI820146B (zh) * 2018-06-15 2023-11-01 瑞典商阿斯特捷利康公司 嘌呤酮化合物及其在治療癌症中之用途
CN114315834B (zh) * 2020-04-17 2024-01-05 成都百裕制药股份有限公司 咪唑啉酮衍生物及其在医药上的应用
KR102409595B1 (ko) * 2020-06-29 2022-06-17 한국과학기술연구원 단백질 카이네이즈 csf-1r 억제제로서의 신규 퓨리논 유도체
CZ309356B6 (cs) * 2020-09-15 2022-09-28 Ústav experimentální botaniky AV ČR, v. v. i Substituované purinové sloučeniny jako inhibitory proteinkináz, jejich použití jako léčiva a farmaceutické přípravky obsahující tyto deriváty
WO2022135360A1 (fr) * 2020-12-21 2022-06-30 江苏恒瑞医药股份有限公司 Dérivé de purinone, son procédé de préparation et son utilisation en médecine
WO2022199547A1 (fr) * 2021-03-22 2022-09-29 成都赜灵生物医药科技有限公司 Dérivé de 7,9-dihydropurine et son usage pharmaceutique
CN117321057A (zh) * 2021-08-23 2023-12-29 成都百裕制药股份有限公司 一种咪唑啉酮衍生物的制备工艺及其中间体
EP4406955A1 (fr) * 2021-09-23 2024-07-31 Chengdu Baiyu Pharmaceutical Co., Ltd. Forme cristalline d'un dérivé d'imidazolinone
WO2024012516A1 (fr) * 2022-07-13 2024-01-18 成都百裕制药股份有限公司 Utilisation d'un dérivé d'imidazolinone en combinaison avec une radiothérapie dans le traitement de tumeurs
WO2024017220A1 (fr) * 2022-07-20 2024-01-25 成都百裕制药股份有限公司 Utilisation d'un dérivé d'imidazolinone associé à la doxorubicine dans le traitement de tumeurs
WO2024125304A1 (fr) * 2022-12-13 2024-06-20 成都百裕制药股份有限公司 Préparation pharmaceutique de composé d'imidazolinone, son procédé de préparation et son utilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2594425A1 (fr) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Pyrimidines heterocycliques anneles a 5 elements utilises comme inhibiteurs de kinase
WO2006091737A1 (fr) * 2005-02-24 2006-08-31 Kemia, Inc. Modulateurs de l'activite de gsk-3
TWI398252B (zh) * 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途

Also Published As

Publication number Publication date
BRPI0815709A2 (pt) 2017-06-13
CO6260060A2 (es) 2011-03-22
ECSP10010034A (es) 2010-04-30
NZ584138A (en) 2011-10-28
NI201000032A (es) 2010-12-07
SV2010003491A (es) 2010-07-06
CN103298814A (zh) 2013-09-11
EA201000341A1 (ru) 2010-10-29
MX2010002115A (es) 2010-06-01
EP2212326A1 (fr) 2010-08-04
CA2696200A1 (fr) 2009-02-26
KR20100057650A (ko) 2010-05-31
AU2008290330A1 (en) 2009-02-26
WO2009024824A1 (fr) 2009-02-26
JP2010536841A (ja) 2010-12-02
CR11295A (es) 2010-05-28
US20110118238A1 (en) 2011-05-19
DOP2010000064A (es) 2010-03-31

Similar Documents

Publication Publication Date Title
ZA201001193B (en) 2-anilinopurin-8-ones as inhibitors of TTK/MPS1 for the treatment of proliferative disorders
IL201650A0 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
EP2063897A4 (fr) Inhibiteurs de kinases utiles pour le traitement de maladies prolifératives
EP2063896A4 (fr) Inhibiteurs de la kinase utiles dans le traitement de maladies prolifératives
HRP20181608T1 (hr) Korištenje inhibitora pde7 u liječenju bolesti kretanja
HK1129890A1 (en) C-met protein kinase inhibitors for the treatment of proliferative disorders
HK1139036A1 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
ZA201000106B (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
ZA201000087B (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
EP2313091A4 (fr) Compositions pharmaceutiques contenant des inhibiteurs de ret et procédés de traitement du cancer
EP2211854A4 (fr) Procédés et compositions pour le traitement du cancer au moyen d'inhibiteurs de parp de type benzopyrone
ZA200906210B (en) 3-Imidazolyl-Indoles for the treatment of proliferative diseases
HK1166314A1 (en) Oxazine derivatives and their use as bace inhibitors for the treatment of neurological disorders bace
EP2429292A4 (fr) Composés et compositions comprenant des inhibiteurs des cdk et méthodes de traitement du cancer
EP1981526A4 (fr) L'adiponectine pour le traitement de divers troubles
EP2488025A4 (fr) Inhibiteurs de sépiaptérine réductase pour le traitement de la douleur
ZA201102520B (en) Pyridine and pyrimidine based compounds as wnt signaling pathway inhibitors for the treatment of cancer
EP2139475A4 (fr) Utilisation d'inhibiteurs pde7 dans le traitement des troubles du
IL207046A (en) Quinazoline derivatives for the treatment of cancer-related disorders
ZA201001264B (en) 1-amino-alkylcycohxane derivatives for the treatment of cochleat tinnitus
ZA201002167B (en) Treatment regime for proliferative disorders
HK1141447A1 (en) Pharmaceutical composition for the treatment of proliferative diseases
HK1232162A1 (zh) 治療疼痛症狀及其它失調的化合物
EP2142566A4 (fr) Procedes et compositions pour le traitement de maladies proliferatives
EP2456437A4 (fr) Thérapie de combinaison pour des tauopathies